Previous 10 | Next 10 |
– Efficacy and Safety Profile of Once-Daily Vemlidy Demonstrated in Children Six Years of Age (Weighing at Least 25kg) and Older – Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental new ...
2024-03-28 08:23:29 ET Gilead Sciences ( NASDAQ: GILD ) has signed an exclusive license deal to develop and commercialize Xilio Therapeutics’ ( NASDAQ: XLO ) XTX301, an investigational tumor-activated IL-12 program with potential to treat a broad range of cancers....
— Gilead Granted Exclusive License to Xilio’s Tumor-Activated IL-12 Program, Including XTX301, a Clinical-Stage IL-12 Molecule with Potential to Treat a Broad Range of Cancers — Gilead Sciences, Inc. (Nasdaq: GILD) and Xilio Therapeutics, Inc. (Nasdaq: XLO) today an...
2024-03-27 02:09:28 ET Summary Our 3-step process focuses on wide-moat stocks (as per Morningstar’s rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may b...
NORTHAMPTON, MA / ACCESSWIRE / March 26, 2024 / Dr. Thomas Odeny grew up in rural Kenya during the height of the HIV epidemic in sub-Saharan Africa. After graduating from medical school at the University of Nairobi, he decided to begin his career in HIV care as a way to give back to his communit...
2024-03-24 08:37:16 ET Summary A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates. Companies with upcoming pay dates. Introduction The D...
2024-03-22 17:37:29 ET More on Gilead Sciences Gilead Sciences Finally Starts Succeeding Gilead Sciences: Realizing Financial Projections Is Key Gilead Sciences, Inc. (GILD) Barclays 26th Annual Global Healthcare Conference (Transcript) Dividend Roundup: Qual...
Acquisition Reinforces Gilead’s Leadership in Developing Innovative Therapies For Challenging Liver Diseases Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction to acquire CymaBay Therapeutics, Inc. (Nasdaq: CBAY) for appr...
2024-03-21 04:43:11 ET Summary Gilead Sciences has a strong track record in curing Hepatitis C and a successful HIV business. The company has struggled with acquisitions but is expected to generate strong shareholder returns. Gilead Sciences has new businesses and milestones p...
2024-03-20 13:10:49 ET Summary Gilead Sciences has seen weak price momentum over the past year following the sales drop in its COVID-19 medication Veklury, even as sales-ex Veklury look alright and earnings have grown. The company has a relatively positive revenue and earnings gui...
News, Short Squeeze, Breakout and More Instantly...
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2024 financial results and guidance will be released on Thursday, August 8, 2024, after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’...
– New 5-Year Clinical and Real-World Data Reinforce Biktarvy ® as a Long-Term Treatment Option for a Diverse Range of People with HIV, Including Those with Comorbidities – – Investigational, Once-Daily, Once-Weekly and Twice-Yearly Dosing Frequenc...
– PURPOSE 1 Data Showed Zero Infections and 100% Efficacy and Superiority of Lenacapavir to Background HIV Incidence and Daily Truvada ® for PrEP – – If Approved, Lenacapavir Would be the First and Only Twice-Yearly PrEP Choice and Could Address C...